BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

935 related articles for article (PubMed ID: 30832741)

  • 1. Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau).
    Gibbons GS; Kim SJ; Robinson JL; Changolkar L; Irwin DJ; Shaw LM; Lee VM; Trojanowski JQ
    Acta Neuropathol Commun; 2019 Mar; 7(1):34. PubMed ID: 30832741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
    Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
    J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies.
    Thal DR; von Arnim CA; Griffin WS; Mrak RE; Walker L; Attems J; Arzberger T
    J Neural Transm (Vienna); 2015 Jul; 122(7):1007-18. PubMed ID: 25556950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies.
    Pires G; McElligott S; Drusinsky S; Halliday G; Potier MC; Wisniewski T; Drummond E
    Acta Neuropathol Commun; 2019 Dec; 7(1):195. PubMed ID: 31796108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau).
    Dickson DW; Kouri N; Murray ME; Josephs KA
    J Mol Neurosci; 2011 Nov; 45(3):384-9. PubMed ID: 21720721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.
    Irwin DJ; Lleó A; Xie SX; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    Ann Neurol; 2017 Aug; 82(2):247-258. PubMed ID: 28719018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent tau pathologies in frontotemporal lobar degeneration with TDP-43 pathology.
    Koga S; Zhou X; Murakami A; Fernandez De Castro C; Baker MC; Rademakers R; Dickson DW
    Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12778. PubMed ID: 34823271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
    Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies.
    Tagai K; Ono M; Kubota M; Kitamura S; Takahata K; Seki C; Takado Y; Shinotoh H; Sano Y; Yamamoto Y; Matsuoka K; Takuwa H; Shimojo M; Takahashi M; Kawamura K; Kikuchi T; Okada M; Akiyama H; Suzuki H; Onaya M; Takeda T; Arai K; Arai N; Araki N; Saito Y; Trojanowski JQ; Lee VMY; Mishra SK; Yamaguchi Y; Kimura Y; Ichise M; Tomita Y; Zhang MR; Suhara T; Shigeta M; Sahara N; Higuchi M; Shimada H
    Neuron; 2021 Jan; 109(1):42-58.e8. PubMed ID: 33125873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glial reactivity and T cell infiltration in frontotemporal lobar degeneration with tau pathology.
    Hartnell IJ; Woodhouse D; Jasper W; Mason L; Marwaha P; Graffeuil M; Lau LC; Norman JL; Chatelet DS; Buee L; Nicoll JAR; Blum D; Dorothee G; Boche D
    Brain; 2024 Feb; 147(2):590-606. PubMed ID: 37703311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.
    Lleó A; Irwin DJ; Illán-Gala I; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    JAMA Neurol; 2018 Jun; 75(6):738-745. PubMed ID: 29554190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease.
    Ando K; Tomimura K; Sazdovitch V; Suain V; Yilmaz Z; Authelet M; Ndjim M; Vergara C; Belkouch M; Potier MC; Duyckaerts C; Brion JP
    Neurobiol Dis; 2016 Oct; 94():32-43. PubMed ID: 27260836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
    Soleimani-Meigooni DN; Iaccarino L; La Joie R; Baker S; Bourakova V; Boxer AL; Edwards L; Eser R; Gorno-Tempini ML; Jagust WJ; Janabi M; Kramer JH; Lesman-Segev OH; Mellinger T; Miller BL; Pham J; Rosen HJ; Spina S; Seeley WW; Strom A; Grinberg LT; Rabinovici GD
    Brain; 2020 Dec; 143(11):3477-3494. PubMed ID: 33141172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration.
    Ghirelli A; Tosakulwong N; Weigand SD; Clark HM; Ali F; Botha H; Duffy JR; Utianski RL; Buciuc M; Murray ME; Labuzan SA; Spychalla AJ; Pham NTT; Schwarz CG; Senjem ML; Machulda MM; Baker M; Rademakers R; Filippi M; Jack CR; Lowe VJ; Parisi JE; Dickson DW; Josephs KA; Whitwell JL
    Ann Neurol; 2020 Nov; 88(5):1009-1022. PubMed ID: 32869362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Pathogenesis of the Tauopathies.
    Götz J; Halliday G; Nisbet RM
    Annu Rev Pathol; 2019 Jan; 14():239-261. PubMed ID: 30355155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF tau microtubule-binding region identifies pathological changes in primary tauopathies.
    Horie K; Barthélemy NR; Spina S; VandeVrede L; He Y; Paterson RW; Wright BA; Day GS; Davis AA; Karch CM; Seeley WW; Perrin RJ; Koppisetti RK; Shaikh F; Lago AL; Heuer HW; Ghoshal N; Gabelle A; Miller BL; Boxer AL; Bateman RJ; Sato C
    Nat Med; 2022 Dec; 28(12):2547-2554. PubMed ID: 36424467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective tau tyrosine nitration in non-AD tauopathies.
    Reyes JF; Geula C; Vana L; Binder LI
    Acta Neuropathol; 2012 Jan; 123(1):119-32. PubMed ID: 22057784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response.
    Thal DR; Del Tredici K; Ludolph AC; Hoozemans JJ; Rozemuller AJ; Braak H; Knippschild U
    Acta Neuropathol; 2011 Nov; 122(5):577-89. PubMed ID: 21935637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Argyrophilic grain disease and Alzheimer's disease are distinguished by their different distribution of tau protein isoforms.
    Tolnay M; Sergeant N; Ghestem A; Chalbot S; De Vos RA; Jansen Steur EN; Probst A; Delacourte A
    Acta Neuropathol; 2002 Oct; 104(4):425-34. PubMed ID: 12200631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed TDP-43 proteinopathy and tauopathy in frontotemporal lobar degeneration: nine case series.
    Kim EJ; Brown JA; Deng J; Hwang JL; Spina S; Miller ZA; DeMay MG; Valcour V; Karydas A; Ramos EM; Coppola G; Miller BL; Rosen HJ; Seeley WW; Grinberg LT
    J Neurol; 2018 Dec; 265(12):2960-2971. PubMed ID: 30324308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.